Targeting of lanthanide(III) chelates of DOTA-type glycoconjugates to the hepatic asyaloglycoprotein receptor: cell internalization and animal imaging studies by Prata, M. I. M. et al.
Full Paper
Targeting of lanthanide(III) chelates of DOTA-type
glycoconjugates to the hepatic asyaloglycoprotein
receptor: cell internalization and animal imaging studies
M. I. M. Prata1, A. C. Santos1, S. Torres2, J. P. Andre´2, J. A. Martins2, M. Neves3, M. L. Garcı´a-Martı´n4,
T. B. Rodrigues4,5, P. Lo´pez-Larrubia4, S. Cerda´n4 and C. F. G. C. Geraldes5*
1Instituto de Biofı´sica e Biomatema´tica, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal
2Centro de Quı´mica, Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal
3Instituto Tecnolo´gico e Nuclear, Sacave´m, Portugal
4Instituto de Investigaciones Biome´dicas ‘Alberto Sols’, CSIC-UAM, Madrid, Spain
5Departamento de Bioquı´mica, Centro de RMN e Centro de Neurocieˆncias e Biologia Celular, Faculdade de Cieˆncias e Tecnologia,
Universidade de Coimbra, Coimbra, Portugal
Received 10 May 2006; Revised 31 July 2006; Accepted 28 August 2006
ABSTRACT: The characterization of a new class of hydrophilic liver-targeted agents for g-scintigraphy andMRI, consisting,
respectively, of [153Sm]3þ or Gd3þ complexes of DOTAmonoamide or bisamide linked glycoconjugates (DOTA¼ 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid), is reported. In vitro studies show high uptake of radiolabeled [153Sm]-
DOTAGal2 by the human hepatocyte carcinoma cell line Hep G2 containing the asialoglycoprotein receptor (ASGP-R),
which is decreased to less than 50% by the presence of its high-affinity ligand asialofetuin (ASF). In vivo biodistribution, g-
imaging and pharmacokinetic studies on Wistar rats using the [153Sm]3þ-labeled glycoconjugates show a high uptake in the
receptor-rich organ liver of the radiolabeled compounds containing terminal galactosyl groups, but very little uptake for those
compounds with terminal glycosyl groups. Blocking the receptor in vivo reduced liver uptake by 90%, strongly suggesting
that the liver uptake of these compounds is mediated by their binding to the asyaloglycoprotein receptor (ASGP-R). This
study also demonstrated that the valency increase improves the targeting capability of the glycoconjugates, which is also
affected by their topology. However despite the specific liver uptake of the radiolabeled galactose-bearing multivalent
compounds, the animal MRI assessment of the corresponding Gd3þ chelates shows liver-to-kidney contrast effects which are
not significantly better than those shown by GdDTPA. This probably results from the quick wash-out from the liver of these
highly hydrophilic complexes, before they can be sufficiently concentrated within the hepatocytes via receptor-mediated
endocytosis. Copyright # 2006 John Wiley & Sons, Ltd.
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INTRODUCTION
In humans and animals, oligosacharides are covalently
bound to proteins (glycoproteins) and lipids (glycolipids)
and control a wide variety of cellular processes. These
functions are mediated by a class of membrane receptor
proteins belonging to the general family of lectins.
Lectins are monomeric or (homo/hetero)-oligomeric
proteins, either soluble or membrane-bound, bearing a
single or multiple carbohydrate recognizing domain(s)
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(CRD) per subunit (1,2). The CRDs interact specifically
with sugars (glucose, mannose, galactose, etc) with
affinity constants (lectin-monomeric sugar) (Kd) in the
milimolar range (3). Assembly of monomeric units
produces oligomeric lectins displaying an array of CRDs
with a variety of topologies (4). Often one or both of the
interacting sugar–lectin partners are membrane-bound. A
membrane-bound lectin (receptor) may recognize a
soluble or a membrane-bound oligosaccharide (5). Both
types of interactions are appealing for pharmacologic
intervention as long as the intrinsically low monomeric
sugar–lectin affinity can be overcome (6). The use of
soluble multivalent glycoconjugate constructs displaying
a cluster glycosid effect is mandatory for the targeting of
cell/organ-specific lectins for drug delivery purposes and
for the inhibition of cell–cell or cell–foreign body
(bacteria/virus) interactions (7,8). The hepatic asialogly-
coprotein receptor (ASGP-R) is an organ-specific lectin,
not found anywhere else in the body except on the surface
of hepatocytes. This hetero-oligomeric lectin has affinity
for terminal b-galactoside and b-N-acetyl-galactosaminyl
residues on glycoproteins. Although its precise function
in vivo is still unclear, it is involved in selectively
removing de-sialylated glycoproteins, with exposed
terminal galactose residues, from serum (9). In addition
to asialoglycoproteins, the ASGP-R recognizes b-
galactoside and N-acetyl-b-galactosaminyl residues
appended to a variety of artificial molecular scaffolds
(10–13).
Annually many people die worldwide of liver cancer
following hepatitis B. The functional imaging of liver
ASGP-R is of both diagnostic and prognostic value during
treatment of liver cancer and other liver conditions (14–
16). Molecular constructs bearing efficient reporter groups
and pendant b-galactoside and/or N-acetyl-b-galactosa-
minyl residues can lead to hepatocyte-specific imaging
agents for liver (11,14–16). A conjugate of a neoglyco-
protein, galactosylated serum albumin (GSA), with
[99mTc]-DTPA (diethylene triamine pentaacetic acid),
[99mTc]-DTPA-GSA, has been used in SPECT (single
photon emission computed tomography) hepatic imaging
to assess the ASGP-R function in mice (17). The
hepatocyte-specific nature of the ASGP-R and the fact
that it is still expressed (although in reduced numbers) on
hepatoma cells makes it possible to detect liver cancer
metastases to other organs. The same imaging agent,
[99mTc]-DTPA-GSA, has been demonstrated to be
clinically useful in humans to detect liver cancer
metastases to the bones (18) and to assess de dynamics
of the ASGP-R internalization/recycling to the surface
of the hepatocytes (19,20). A GdDTPA conjugate of
polylysine (PL) derivatized with galactosyl groups
(GdDTPA-gal-PL) (21), as well as a spin-labeled
arabinogalactan (22), have also been developed as
macromolecular potential contrast agents for liver MRI
by targeting the hepatocyte ASGP-R. A variety of
particulate systems targeted to the ASGP-R have also
been tested in cells and mice as potential contrast agents
for liver MRI: monocrystalline iron oxide nanoparticles
(MION) conjugated to the bovine plasma protein
asialofetuin (ASF), MION-ASF (23), arabinogalactan
(AG)-coated ultra-small superparamagnetic iron oxide
particles (USPIO), AG-USPIO (24–27). Both the macro-
molecular and particle-based ASGP-R-targeted imaging
agents described above include carriers bearing multiple
reporter groups and a multivalent display of galactosyl
targeting groups. However these agents are inherently
polydisperse and ill characterized. Chemically well-
defined and characterized multivalent agents can be
assembled by an alternative molecular design: the
conjugation of dendrimeric clustered carbohydrate bifunc-
tional reagents (monodisperse, well defined and charac-
terized) to a reporter group (28). The resulting conjugates
are of substantially lower molecular weight, higher
stability and greater biological safety. Previous to our
report on the synthesis of dendrimeric multivalent
glycoconjugates of metal complexes for molecular
imaging (MRI and scintigraphy) (29–31), only a study
describing the use of a low molecular weight, well-
characterized, monomeric [111In]-radiolabeled galactopyr-
anosyl conjugate of DOTA (1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid) for the targeting of the
ASGP-R both in hepatic cell lines and mice had appeared
in the literature (32). The design of lectin-targeted MRI
imaging agents includes a reporter group, consisting of a
chelator binding lanthanide(III) ion with high kinetic and
thermodynamic stability, and a targeting group consisting
of a clustered carbohydrate of variable valence, containing
an increasing number of terminal galactosyl groups and
capable of interacting with high affinity and selectivity
with endogenous lectins such as the ASGP-R (3,29–31).
Here we report the radiolabeling of a series of
glycoconjugates based on DOTA-monoamide and bisa-
mide functionalized chelators (Fig. 1) with [153Sm]3þ and
their evaluation using in vitro studies in the human
hepatocyte carcinoma cell line Hep G2. DOTA-like
chelators are well known to form lanthanide(III) chelates
of high thermodynamic and kinetic stability, which is of
crucial importance for in vivo applications (33). Dynamic
g-scintigraphic studies of the pharmacokinetics of the
[153Sm]3þ-labeled glycoconjugates and their biodistribu-
tion inWistar rats are also described, revealing the effect of
valence and type of the terminal sugar moiety on their liver
targeting efficacy. We also report an in vivo MRI study of
the contrast effects and pharmacokinetics of the Gd3þ
complexes of the divalent glycoconjugates DOTALac2
(2c), DOTAGal2 (2a) and DOTAGlc2 (2b) (Fig. 1) in mice,
compared with a typical commercial, small molecular
weight contrast agent, GdDTPA (Magnevist1).
EXPERIMENTAL
The synthesis of the monovalent DOTAGal, DOTALac
and DOTAGlc (1), divalent DOTAGal2, DOTALac2 and
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DOTAGlc2 (2) and tetravalent DOTAGal4 (4) monoamide
glycoconjugate ligands (29), as well as of the divalent
DO2A(cis)Gal2 bisamide (3) ligand (31), have been
described previously.
Reagents for cell interaction, g-imaging and
biodistribution studies
[153Sm]Samarium chloride ([153Sm]Cl3) was produced at
the ITN (Instituto Tecnolo´gico e Nuclear), Lisbon, with a
specific activity >5 GBq/mg. For this purpose, [153Sm]
samarium oxide ([153Sm]2O3) was prepared from a 98%
[152Sm]-enriched samarium oxide target, sealed into a
quartz vial and welded into an aluminium can, by neutron
irradiation using a thermal flux of 2.3 1013 n/cm2 s.
Following irradiation, the sample was opened, dissolved
in 1 M HCl and the final [153Sm]samarium chloride
(153SmCl3) was brought to a stock concentration of
1.9 103 M.
Radiotracer preparation
Stock solutions of the ligands were prepared in isotonic
HEPES buffer (pH 7) or sodium acetate buffer (0.4 M,
Figure 1. Structure of monovalent (1), divalent (2 and 3) and tetravalent (4) glycoconjugate
ligands.
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pH 5); and mixed with [153Sm]samarium chloride and the
solution was heated at 608C for 3 h. A quality control
was performed by thin-layer chromatography (TLC),
using water:ethanol:dicloromethane:ammonia, 5:5:5:1,
as eluent.
Serum stability
To 3ml of fresh human serum previously equilibrated in a
5% CO2 (95% air) environment at 378C, was added 5mCi
of the [153Sm]-DOTAGal standard solution. The mixture
was stored in a 378C environment. At appropriate periods
of time (0, 30min, 1 and 4 h) 100mL aliquots (in
triplicate) were removed and treated with 200mL of
ethanol. Samples were then cooled (48C) and centrifuged
for 15min, at 4000 rpm and 48C, to precipitate serum
proteins. A 100mL aliquot of supernatant was removed
for activity counting in a g well-counter. The sediment
was washed twice with 1ml of ethanol and counted. The
activities in the supernatant and in the pellet were
compared as (activity in the pellet/activity in super-
natant) 100.
In vitro cell interaction studies
Hep G2 human hepatoma cell line (ECACC, UK) was
grown in 75ml bottles with MEM (minimum essential
medium) from Sigma, supplemented with 10% FBS (fetal
bovine serum) from Gibco Invitrogen, and non-essential
aminoacids, glutamine and penicillin/streptomycin, all
from Sigma. The cells were counted and transferred to a
six-hole multiwell plate (0.2 million cells/hole), 2ml of
medium were added to each hole and then the cells were
incubated at 378C, under 5%CO2 for the period necessary
to obtain cell confluence. This is needed because the
human hepatocyte carcinoma line Hep G2 expresses
maximum receptor activity only in confluent cultures
(34). The medium was changed every day. On the day of
the experiments the medium was removed and the cells
were washed twice with 1.5ml medium before adding
1.2ml medium and they were allowed to adjust for 1 h at
378C. Approximately 1mCi of radioligand was added in
each well to the medium and the cells were incubated for
30min and 1 and 2 h at 378C. To three of the holes in each
plate was added an excess of asialofetuin (Sigma; 200ml
of a 0.2mg/ml solution) (32) to evaluate the contribution
of nonspecific contributions to the cell uptake of the
glycoconjugates. At appropriate time periods the exper-
iment was stopped by removal of the medium and
washing the cells twice with 750ml ice-cold phosphate
buffered saline. The medium plus PBS was collected to
tubes to measure the radioactivity. Finally, the cells were
treated with 1 M NaOH (1ml) and incubated at 378C for
10min, to detach them from the plates, and the
radioactivity was measured in a g-counter. Each
experiment was carried out simultaneously in triplicate.
In vivo g-imaging
A g camera-computer system (GE 400 GenieAcq, from
General Electric, Milwaukee, WI, USA) was used for
acquisition and pre-processing. Data processing and
display were performed on a personal computer using
homemade software developed for the IDL 5.2 computer
tool. Awell counter (DPC-Gamma C12, LA, USA) with a
Compaq DeskPro compatible computer was used for
activity counting in the biodistribution studies.
Gamma images and biological distribution for the
[153Sm]3þcomplexes were determined using (200–250 g)
Wistar rats. All animal studies were carried out in
compliance with procedures approved by the appropriate
institutional review committees. Conscious rats were
allowed free access to food and water. Groups of four
animals (one group for each complex) were anesthetized
with ketamine (50mg/ml)–chloropromazine (2.5%)
(10:3) and injected in the femoral vein with ca.
400mCi of the respective [153Sm]3þchelate. The animals
were then positioned in dorsal decubitus over the detector.
Image acquisition was initiated immediately after radio-
tracer injection. Sequences of 180 images (of 10 s each),
were acquired to 64 64 matrices. In addition, static data
were acquired 24 h after the radiotracer injection.
Images were subsequently processed using an IDL
based program (Interactive Data Language, Research
Systems, Boulder, CO, USA). In order to analyze the
transport of radiotracer over time, three regions of interest
(ROI) were drawn on the image files, corresponding to the
thorax, liver and left kidney. From these regions, time–
activity curves were obtained.
Biodistribution studies
Groups of four animals were injected in the tail vein with
ca. 100mCi of the respective [153Sm]3þ tracer and
sacrificed 1 h later. The major organs were excised,
weighed and tissue radioactivity measured in a g well-
counter. Similar biodistribution studies were also
performed with the animals referred to in the previous
section sacrificed at 24 h. For determination of non-
specific uptake on receptor-positive organs, a group of
four animals was co-injected in the femoral vein with a
solution of asialofetuin in NaCl (2mg/ml; injected
volume, 200ml, 0.2mg asialofetuin/100 g body weight)
and [153Sm]3þ–DOTAGal2 (200ml).
Magnetic resonance imaging
The MRI experiments were performed on a Bruker
Pharmascan system (Bruker Medical Gmbh, Ettlingen,
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Germany) using a 7.0 T horizontal-bore superconducting
magnet, equipped with a 1H selective birdcage resonator
of 38mm and a Bruker gradient insert with 90mm
diameter (maximum intensity 300mT/m). All the data
were acquired using a Hewlett-Packard console running
Paravision software (Bruker Medical Gmbh, Ettlingen,
Germany) operating on a Linux platform. Anesthesia was
initiated by inhalation in an induction box with O2 (1 l/
min) containing 3% isofluorane, and maintained during
the experiment using a mask and 1–2% isofluorane in O2.
Animals, albine Swiss male mice, weighing 19–26 g,
were taped down gently into a holder, to minimize
breathing-related motion, and were then placed in a
heated probe, which maintained the core body tempera-
ture at approximately 378C, monitored by a rectal probe.
The physiological state of the animal was monitored by a
Biotrig physiological monitor (Bruker Medical Gmbh,
Ettlingen, Germany) using the respiratory rate and body
temperature. The contrast agents were injected as a
bolus of 50ml via a tail vein catheter at a dose of 0.3mmol
Gd kg1 body weight (BW), except for GdDTPA
(Magnevist1, Schering AG, Berlin, Germany), where a
dose of 0.2mmol Gd kg1 BW was used.
For anatomical reference, a multi-slice rapid acqui-
sition and relaxation enhancement (RARE) sequence
(35) was performed with the following parameters:
RARE factor¼ 8, TR¼ 4000ms, effective TE¼ 65ms,
averages¼ 2, six coronal slices, slice thickness 1.2mm,
FOV¼ 3.8 cm, matrix¼ 256 256. Then, regional
contrast agent uptake was assessed. A series of T1-
weighted spin echo images was sequentially acquired
over 1 h following the injection of the contrast agent.
The acquisition parameters were: TR¼ 155ms, TE¼
11.76ms, averages¼ 2, six coronal slices, slice thick-
ness 1.2mm, FOV¼ 3.8 cm, matrix¼ 256 256, 60
repetitions with temporal resolution 59.31 s.
MRI data processing
Data were analyzed with software written in-house in
IDL. With the aim of comparing the pharmacokinetics
obtained from different animals, the data were normalized
by calculating the relative, rather than the absolute,
enhancement (RE):
RE ¼ ðI  I0Þ
I0
 100
where I is the signal intensity at any given time after
contrast agent (CA) injection and I0 is the intensity before
injection.
Pharmacokinetics were analyzed by calculating the
average enhancements within four different ROIs placed
on the liver, kidney medulla, kidney cortex and muscle.
RESULTS AND DISCUSSION
Studies of [153Sm]3R-radiolabeled
glycoconjugates
Quality control analysis. All the radioactive com-
plexes where analysed by TLC for radiochemical purity
determination as described in the Experimental section.
The radiochemical purity was>98% for all the [153Sm3þ]
complexes with a specific activity ca 2mCi/mmol.
Stability in serum. The percentage of radioactivity in
the non-proteic fraction of human serum incubated with
Figure 2. Uptake of [153Sm]3þ–DOTAGal2, stated as a percentage of added activity, by 1
million Hep G2 cells incubated at different times at 378C, 5% CO2 with the radioligand
(non-blocked experiments) and effect of the addition of an excess of asialofetuin to the
cells (blocked experiment).
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Figure 4. Time–activity curves at the various ROIs in Wistar rats for: from
bottom to top [153Sm]3þ–DOTALac2, [
153Sm]3þ–DOTAGlc2 and [
153Sm]3þ–
DOTAGal2.
Figure 3. Scintigraphic images of Wistar rats at 30min after injection with (from left to right)
½153Sm3þ–DOTAGal2 and ½153Sm3þ–DOTAGlc2.
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Figure 5. Biodistribution in Wistar rats: (a) [153Sm]3þ–DOTA glycoconjugates at 1 h post-
injection; (b) ½153Sm3þ–DOTA glycoconjugates at 24 h post-injection; (c) 1 h after i.v.
co-injection of ½153Sm3þ–DOTAGal2 and excess of asialofetuin (block) or without excess
of asialofetuin (non-block); results are the means of groups of four animals.
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5mCi of the [153Sm]3þ-labeled chelates slowly decays as
a function of time (data not shown). For example, in the
case of [153Sm]3þ–DOTAGal ca 90% of the activity
remained in the non-proteic fraction after 4 h.
Cell uptake. The Hep G2 human hepatocyte carcinoma
cell line is known to express ASGP-R both in vivo and
in vitro (34,36). Figure 2 shows the time dependence of
the radioligand [153Sm]3þ–DOTAGal2 uptake in Hep G2
at 378C with and without ASGP-R blocking. In these
conditions, unblocked cell uptake increases with time,
reaching 12.6% of the added activity after 2 h, but without
reaching a plateau within the 2 h incubation. The cell
activity uptake is reduced in the presence of an excess of
the ASGP-R blocker asialofetuin (Fig. 2). However, the
observed reduction of the radioligand uptake in the
presence of excess asialofetuin is smaller than expected if
the radioligand bound exclusively to the ASGP-R,
especially at short incubation times. This indicates
significant nonspecific cell internalization through an
unknown mechanism. The specific/nonspecific internal-
ization ratio reaches a maximum at 2 h, when the cell
uptake becomes less than 40% of the non-blocked value
(the two tailed t-test for the 2 h results gives p¼ 0.002
while for 30min and for 1 h p> 0.04), in agreement with
similar uptake studies with an [111In]3þ-labeled DOTA-
Gal monoamide (32).
In vivo g-imaging and biodistribution. Figure 3
shows scintigraphic images of Wistar rats obtained
30min after tracer injection for [153Sm]3þ-labeled
DOTAGal2 (2a) and DOTAGlc2 (2b) conjugates. There
is a noticeably high uptake of [153Sm]3þ–DOTAGal2 by
liver (left image), correlating with the fact that the surface
of liver parenchimal cells contain a very high density of
ASGP-R, about 500,000 per cell (37,38), which can
selectively take up the radiotracer by receptor mediated
endocytosis (32). In the left image the bladder is also
seen, which reflects the renal excretion pathway of these
hydrophilic compounds. In addition, a very rapid
clearance occurs from all other organs, in accordance
with the biodistribution data obtained in the same animals
(see below). A quite different behavior is found in rats
injected with [153Sm]3þ–DOTAGlc2 (right image), as the
activity is localized only in the kidneys. No liver uptake is
observed, which is consistent with the fact that glucosyl
glycoconjugates are not recognized by the ASGP-Rs (39).
The time–activity curves for the [153Sm]3þ-labeled
glycoconjugates were obtained from the dynamic
acquisition experiments (Fig. 4). The curves were
smoothed and normalized in relation to the maximum
activity obtained for each radiolabeled glycoconjugate.
While the activity of [153Sm]3þ–DOTAGal2 is higher in
the liver than in the kidney, and steadily increases up to
the 30min time interval in both organs, the activity of
[153Sm]3þ–DOTAGlc2 quickly rises in kidney to a much
higher value than in liver, reaching a maximum at 5min,
and then slowly decays. The initial behavior of
[153Sm]3þ–DOTALac2, with a quick activity increase
in kidney, is close to that of [153Sm]3þ–DOTAGlc2, but
after attaining a maximum at 4min, the kidney activity
quicky decreases, while the liver activity steadily rises, as
in [153Sm]3þ–DOTAGal2. This result might be explained
by the higher hydrophilicity of the lactosyl conjugate
relative to the galactosyl conjugate, which determines its
initial concentration in the kidney, after which the
terminal galactosyl groups of the lactosyl derivative bind
to the liver ASGP-Rs. A number of lactosyl conjugates
have been described for liver targeting (40,41).
Biodistribution data for the [153Sm]3þ-radiolabeled
glycoconjugates obtained in Wistar rats are presented in
Figs 5 and 6 and Table 1 as percentages of injected dose
per gram of tissue (%ID/g). The most striking feature
shown by the biodistribution studies at 1 h post-injection
is the high liver targeting ability of the galactosyl
conjugates [Fig. 5(a)]. In sharp contrast, the glucosyl
Figure 6. Comparison of the biodistribution in Wistar rates 1 h after injection of
½153Sm3þ–DO3AGal2 and ½153Sm3þ–DO2AGlc2.
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conjugates show no liver uptake, as they locate mainly in
the kidneys due to their hydrophilicity. The biodistribu-
tion data for the lactosyl conjugates confirm the
intermediate behavior between the galactosyl and
glucosyl conjugates seen in the dynamic acquisition
curves described above.
Another noteworthy finding is the effect of the valence
of the glycoconjugates on the biodistribution pattern.
Whereas the monovalent conjugate [153Sm]3þ–DOTAGal
shows some spleen and lung uptake, the divalent
compound, apart from the kidney, does not appear to a
significant extent in any other organ. The behavior of the
tetravalent compound is very similar to that of the divalent
one (e.g. liver uptake corresponds to 0.91% of the ID/g for
[153Sm]–DOTAGal2 and to 0.82% of the ID/g for
[153Sm]3þ–DOTAGal4), indicating that the effect of the
increase in valence from 2 to 4 does not seem to improve
liver uptake after 1 h. This might be explained by the high
number of ASGP-Rs expressed by each hepatocyte cell
(37,38) and/or some degree of steric crowding of the
galactose residues. However, the effect of the valence of
synthetic and natural glycoconjugates on the affinity to
lectins has been fully demonstrated (7,8) and thus the
expected order of increasing affinity of the glycoconju-
gate ligands for the ASGP-R is tetra> tri> di>mono
(7,8,42,43). This is confirmed by the observed contrast in
the biodistribution behavior between the [153Sm]3þ–
DOTAGal2 and [
153Sm]3þ–DOTAGal4 derivatives after
24 h [Fig. 5(b), Table 1]. The activity remaining in liver at
24 h for the tetravalent radiolabeled glycoconjugate
[153Sm]3þ–DOTAGal4 (0.2% of the ID/g) is much higher
than for the divalent 153Sm3þ–DOTAGal2 (0.002% of the
ID/g), suggesting a greater metabolic stability of the
former compound.
The data in Fig. 5(a) also shows that the three ligands
bearing only one sugar moiety (DOTAGal, DOTAGlc and
DOTALac) stay longer in the blood stream and have a
more dispersed biodistribution pattern than the higher
valence analogs. Binding to some plasma component
might be responsable for this finding. Thus, in addition to
the multivalence effect, subtle structural effects arising
from the dendrimeric framework of these ligands,
especially the tertiary amine nitrogen, might be respon-
sable for the observed differences of biodistribution
between the monovalent and multivalent compounds.
Figure 5(c) shows the biodistribution results of an in
vivo competition experiment using large excess of
asialofetuin, a specific blocker of the ASGP-R, co-
injected with the radioligand [153Sm]3þ–DOTAGal2. In
animals injected with the blocker, activity uptake in liver
was reduced by 90% (p< 0.001) compared with the
blocked animals (32). The injection of the blocking dose
also increased the uptake in the kidneys by a factor of 3,
suggesting that more activity is cleared instead of binding
to the ASGP-R. These results strongly suggest that the
uptake of the radiolabeled glycoconjugate is specific to
the ASGP-R endocytosis. These results are in closeT
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qualitative agreement with that obtained for the
interaction with the Hep G2 cell line, although one
should consider that the total number of ASGP-R
receptors in the human hepatocyte carcinoma cell line
HepG2 is 140 000 65 000 sites per cell (44), signifi-
cantly lower than the value obtained for isolated rat
hepatocytes (37,38).
A DOTA bisamide glycoconjugate bearing two
galactosyl moieties in a cis position, DO2A(cis)Gal2
(Fig. 1) was also evaluated. Figure 6 shows that this new
topology of the targeting groups does not introduce
significant differences in the biodistribution pattern at 1 h,
although the liver targeting ability of the DOTA
monoamide conjugate seems to be superior.
Magnetic resonance imaging
Effect of the Gd chelates on vital functions. The
CAs are well tolerated by the mice. No gross side effects
were observed during injection, immediately or after the
experiment. The animal temperature remained stable
throughout the entire experiment, whereas the respiration
rate slightly increased during the first 2–3min post-
injection.
MRI in vivo. Series of T1-weighted spin echo images of
the dynamic contrast-enhanced (DCE) MRI experiments
with the three divalent DOTA-glycoconjugate chelates of
Gd3þ, GdDOTALac2, GdDOTAGal2 and GdDOTAGlc2
(dose 0.3mmol kg1 BW) and GdDTPA (dose
0.2mmol kg1 BW) are shown in Fig. 7. Before injection,
kidney, liver and muscle did not show any contrast
difference, due to the short TR (155ms) used for the
acquisition of the T1-weigthed images. After injection, a
strong signal enhancement was observed in the kidneys
and vena cava, for the various CAs, as a result of the T1
shortening. A lesser signal enhancement was observed in
liver and muscle for all the CAs. The time courses of the
average relative enhancement of several ROIs of the T1-
weighted spin echo MR images are displayed in Fig. 8.
The scattering in the curves was caused by animal
respiratory motion. The time course of the average
relative enhancement after the injection of 0.2mmol/kg of
GdDTPA [Fig. 8(a)] is in good agreement with the
literature (45). Relative enhancement increased immedi-
ately after injection from 0 up to about 300% in the kidney
medulla and about 150% in the kidney cortex, liver and
muscle. While the enhancement in the later organs
remained constant for about 40min, the kidney medulla
value slowly decreased in that time interval to about
200%. The kidney medulla–liver enhancement ratio
decreased from 2.2 at 4min to 1.5 at 35min. After
injection of GdDOTALac2 [Fig. 8(b)], the relative
enhancement increased up to approximately 350% in
the kidney medulla, 260% in the kidney cortex, 300% in
Figure 7. Axial T1-weighted spin echoMR images ofmice before and after injection of GdDTPA (dose
0.2mmol kg1 BW), GdDOTALac2, GdDOTAGal2 and GdDOTAGlc2 (dose 0.3mmol kg
1 BW). Each
image corresponds to the average of 12min acquisition.
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the liver and 180% in the muscle. These maximum
enhancements were reached at 20, 10, 3–4 and 4–5min
post-injection, respectively, and then decreased with a
slow linear decay. The kidney medulla–liver enhance-
ment ratio increased from 0.6 at 4min to 4.1 at 35min. In
the case of GdDOTAGal2 [Fig. 8(c)], more moderate
increases were observed in all the organs. The relative
enhancement increase was approximately 220% in the
kidney medulla, 150% in the kidney cortex, 100% in the
liver and 80% in the muscle. In all ROIs a plateau was
reached within the first 5min post-injection and remained
constant until the end of the pharmacokinetics exper-
iment, with a constant kidney medulla–liver enhancement
ratio of 1.7. Finally, immediately after the injection of
GdDOTAGlc2 [Fig. 8(d)], a very strong signal rise was
observed, especially in the kidney cortex and medulla,
followed after 3min by signal decay due to an effect of T2
shortening induced by the extremely high concentration
of the CA. This circumstance did not allow the maximum
enhancement to be measured. Nevertheless, from the
measurable points the kidney medulla–liver enhancement
ratio increased from 1.6 at 3min to 5.3 at 35min.
This comparison of the pharmacokinetics data of the
four compounds shows that the glycoconjugate chelates
GdDOTAGlc2 and GdDOTAGal2 behave quite similarly
to GdDTPA throughout the whole time course of the
experiment, with predominant kidney enhancement. In
the case of GdDOTALac2 the initial enhancement of liver
is higher than of kidney, but after 4min the kidney cortex
and medulla effect becomes predominant.
CONCLUSIONS
Hepatobiliary CAs, with selective hepatocyte uptake by
organic anion carriers and biliary excretion, provide a
means of obtaining specific liver MRI enhancement and
improved detection and characterization of small hepatic
lesions (46). Several potential CAs for liver MRI have also
been developed by targeting the hepatocyte ASGP-R and
uptake via its endocytic pathway, such as targeted
particulate T2 relaxation agents (23–27) and macromol-
ecular T1 relaxation agents (21,22). This approach is also
useful in the detection and characterization of hepatic
lesions, as they strongly affect the hepatocyte receptor
levels (21). Appending a small glycodendrimer ending
with galactosyl unit(s) to a GdDOTA scaffold via an amide
bond generates a new class of low molecular weight,
stable, hydrophilic glycoconjugates, of greater biological
safety than the polymeric GdDTPA-gal-PL (21), and
Figure 8. Time course of signal intensity, relative to the initial value (up to 60min post-injection) of several regions
of interest during dynamic contrast enhancement MRI experiments in mice with (A) GdDTPA (dose 0.2mmol kg1
BW), (B) GdDOTALac2 (dose 0.3mmol kg
1 BW), (C) GdDOTAGal2 (dose 0.3mmol kg
1 BW) and (D) GdDOTAGlc2
(dose 0.3mmol kg1 BW). The time courses are data for individual animals.
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with targeting ability for the liver via recognition of
the ASGP-R, as suggested in vitro by Hep G2 cell
uptake, and in vivo g-imaging and biodistribution
studies of the [153Sm]3þ-labeled compounds in Wistar
rats. The glycodendrimer architecture allows variation of
the sugar type and valence in an interactive way from a
reduced number of building blocks. The effect of the
increase of valence on the targeting efficiency is clear
when going from monoderivatives to divalent glycocon-
jugates. The performance of the next generation,
tetravalent glycoconjugates, is similar to that of the
divalent one, at 1 h post-injection. However this com-
pound is retained much longer at its target organ, as
demonstrated by the activity remaining in the liver after
24 h. Moreover, there are important biodistribution
differences between mono- and multivalent glycoconju-
gates (32). A critical feature in the glycoconjugate–ASGP-
R interaction is the topology of both the glycoconjugate
and lectin. In this respect, the relative orientation and
spacing of the carbohydrate residues in the glycoconjugate
in relation to the distribution of the carbohydrate
recognition domains (CRDs) on the ASGP-R is of
fundamental importance in the optimization of their
interaction (47,48).
The superior performance of the multivalent com-
pounds validates our approach to lectin-mediated target-
ing for molecular imaging. The specific uptake of the
galactosyl-bearing compounds via the ASGP-R opened
an opportunity for the use of their Gd3þ chelates as CAs
for ASGP-R mediated liver MRI. However, despite the
promising scintigraphic performance of the galactosyl-
bearing multivalent compounds, the animal MRI assess-
ment of the corresponding Gd3þ chelates shows only
limited liver-to-kidney contrast effects, similar to the
GdDTPA effects. This probably results from the quick
wash-out from the liver to the kidney of these highly
hydrophilic complexes, before they can be concentrated
within the hepatocytes via receptor-mediated endocytosis
up to a concentration high enough to yield a detectable
image contrast (49), limiting their use as CAs for ASGP-
R-mediated molecular imaging. The design of more
efficient hepatocyte-targetMRI agents of this kindmay be
pursued by tuning the hydrophilicity/hydrophobicity
balance of the dendrimeric compounds, through either
structural modification of the dendrimeric backbone or
the sugar-linker moiety, while improving the targeting
ability of themultivalent architecture, and enhancing their
relaxivity by centrally positioning the Gd3þ to provide a
more effective motional coupling of the chelate with the
Gd3þ-proton vector (50).
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